• Explore /
  • Poster
  • / Phase 2 study of camrelizumab (anti-PD-1 antibody) combined with apatinib and chemotherapy for the first-line treatment of advanced esophageal squamous cell carcinoma.

Phase 2 study of camrelizumab (anti-PD-1 antibody) combined with apatinib and chemotherapy for the first-line treatment of advanced esophageal squamous cell carcinoma.

Abstract Poster

Authors

null

Bo Zhang

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Bo Zhang , Ling Qi , Xi Wang , Jun Jiang , Xin Zhang , Yun Liu , Lan Mu , Jing Huang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT03603756

Citation

J Clin Oncol 37, 2019 (suppl; abstr 4033)

DOI

10.1200/JCO.2019.37.15_suppl.4033

Abstract #

4033

Poster Bd #

138

Abstract Disclosures

Similar Posters

First Author: Xiangrui Meng

First Author: Feng Wang

First Author: Jun Ni

First Author: Lulu Ye